Failure of Etretinate Therapy in Twins with Severe Congenital Lamellar Ichthyosis

Yeheskel Waisman, Avinoam Rachmel, Aryeh Metzker, Eliyahu Wielunsky, Menachem Nitzan, Arye Rotem, Reuben Steinherz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Abstract: We cared for twin females with severe lamellar extoliation of the newborn (collodlon babies) and a family history of death of two brothers at age 3 months. The twins were given a controlled trial of etretinate (Ro 10‐9359, Tigason) after not responding to other therapeutic modalities. One of the infants received 1 mg/kg body weight of the drug for 24 hours, while her identical twin sister did not have the medication. Monthly skin biopsies taken from both patients during nine months of therapy did not demonstrate any histologic difference under light microscopy. The clinical course in both infants was basically the same. Etretinate plasma level measurements proved that the drug was absorbed from the gastrointestinal tract. We conclude that in the very severe forms of congenital lamellar ichthyosis, oral retinoids may fail to produce any beneficial effects.

Original languageEnglish
Pages (from-to)226-228
Number of pages3
JournalPediatric Dermatology
Volume6
Issue number3
DOIs
StatePublished - Sep 1989

Fingerprint

Dive into the research topics of 'Failure of Etretinate Therapy in Twins with Severe Congenital Lamellar Ichthyosis'. Together they form a unique fingerprint.

Cite this